Table 2.
CINV Outcomes.
| N = 102 | CR global | CR acute | CR delayed | CP global | CP acute | CP delayed | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | p | N (%) | p | N (%) | p | N (%) | p | N (%) | p | N (%) | p | |
| Sex | ||||||||||||
|
Female n = 44 |
13 (29.5) | 0.088 | 19 (43.2) | 0.855 | 17 (38.6) | 0.322 | 9 (20.5) | 0.517 | 13 (29.5) | 0.377 | 15 (34.1) | 0.479 |
|
Male n = 58 |
9 (15.5) | 24 (41.4) | 17 (29.3) | 9 (15.5) | 22 (37.9) | 16 (27.6) | ||||||
| Type TPH | ||||||||||||
|
Alo n = 45 |
6 (13.3) | 0.072 | 10 (22.2) | 0.0002 | 12 (26.7) | 0.204 | 4 (8.9) | 0.039 | 7 (15.6) | 0.0004 | 11 (24.4) | 0.246 |
|
Auto n = 57 |
16 (28.1) | 33 (57.9) | 22 (38.6) | 14 (24.6) | 28 (49.1) | 20 (35.1) | ||||||
| Conditioning for HSCT | ||||||||||||
| Myeloablative | 19 (27.9) | 0.027 | 36 (52.9) | 0.002 | 27 (39.7) | 0.054 | 16 (23.5) | 0.028 | 30 (44.1) | 0.003 | 24 (35.3) | 0.128 |
|
n = 68 Reduced intensity n = 34 |
3 (8.8) | 7 (20.6) | 7 (20.6) | 2 (5.9) | 5 (14.7) | 7 (20.6) | ||||||
| Antiemetic regimens | ||||||||||||
| Monotherapy: 5HT3 receptor antagonists | 4 (10) | 0.023 | 8 (20) | 0.0003 | 8 (20) | 0.022 | 3 (7.5) | 0.031 | 6 (15) | 0.001 | 31 (30. 4) | 0.067 |
|
n = 40 Bitherapy: 5HT3 receptor antagonists + corticosteroids n = 62 |
48.(77.4) | 35 (56.5) | 26 (41.9) | 15 (24.2) | 29 (46.8) | 23 (37.1) | ||||||
| Emetogenic potential | ||||||||||||
|
High n = 67 |
19 (28.4) | 0.21 | 36 (53.7) | 0.001 | 27 (40.3) | 0.039 | 16 (23.9) | 0.022 | 30 (44.8) | 0.002 | 24 (35.8) | 0.099 |
|
Moderate n = 35 |
3 (8.6) | 7 (20.0) | 7 (20.0) | 2 (5.7) | 5 (14.3) | 7 (20.0) | ||||||
Values are n (%). Acute indicates within 24 h of chemotherapy initiation; delayed, From 24 h after initiation of chemotherapy through 5 days after last day of chemotherapy. CINV: chemotherapy-induced nausea and vomiting; CP: complete protection; CR: complete response; TPH: type of transplant hematopoiesis; HSCT: hematopoietic stem cell transplantation. Analysis via chi-square test.